Skip to content

Whittier Daily News

54°F
Monday, November 24th 2025

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

28.96 +0.79 (+2.80%)
Streaming Delayed Price Updated: 10:38 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings) ↗
 
Via Benzinga
News headline image
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months ↗
In the last three months, IBRX outperformed NVDA by over 3x. 
Via Talk Markets
News headline image
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024 ↗
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
News headline image
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
News headline image
Analyst Ratings For Legend Biotech ↗
 
Via Benzinga
News headline image
Unveiling 9 Analyst Insights On Legend Biotech ↗
 
Via Benzinga
News headline image
Earnings Preview: Legend Biotech ↗
 
Via Benzinga
News headline image
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
News headline image
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
From Legend Biotech Corporation
Via Business Wire
News headline image
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population ↗
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
News headline image
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
News headline image
What 4 Analyst Ratings Have To Say About Legend Biotech ↗
 
Via Benzinga
News headline image
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy ↗
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
News headline image
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
From Legend Biotech Corporation
Via Business Wire
News headline image
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer ↗
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
News headline image
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
News headline image
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers ↗
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
News headline image
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
Via Benzinga
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
News headline image
Earnings Scheduled For March 11, 2024 ↗
Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report quarterly loss at $0.13 per share on revenue of $34.20 million. 
Via Benzinga
News headline image
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
News headline image
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
News headline image
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership ↗
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody... 
Via Talk Markets
News headline image
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
From Legend Biotech Corporation
Via Business Wire
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
From Legend Biotech Corporation
Via Business Wire
News headline image
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
News headline image
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks? ↗
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments. 
Via Benzinga
News headline image
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 ↗
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
News headline image
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
From Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.